These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36946611)

  • 61. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
    Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration.
    Oeckl P; Steinacker P; von Arnim CA; Straub S; Nagl M; Feneberg E; Weishaupt JH; Ludolph AC; Otto M
    J Proteome Res; 2014 Nov; 13(11):4518-25. PubMed ID: 25091646
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
    Chalmers KA; Love S
    J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer's Disease and Frontotemporal Dementias.
    Constantinides VC; Paraskevas GP; Boufidou F; Bourbouli M; Pyrgelis ES; Stefanis L; Kapaki E
    Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832271
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.
    Chatterjee M; Del Campo M; Morrema THJ; de Waal M; van der Flier WM; Hoozemans JJM; Teunissen CE
    Alzheimers Res Ther; 2018 Jun; 10(1):52. PubMed ID: 29859129
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease.
    Lim B; Tsolaki M; Soosaipillai A; Brown M; Zilakaki M; Tagaraki F; Fotiou D; Koutsouraki E; Grosi E; Prassas I; Diamandis EP
    Clin Chem Lab Med; 2019 Nov; 57(12):1875-1881. PubMed ID: 31415236
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
    Cope TE; Rittman T; Borchert RJ; Jones PS; Vatansever D; Allinson K; Passamonti L; Vazquez Rodriguez P; Bevan-Jones WR; O'Brien JT; Rowe JB
    Brain; 2018 Feb; 141(2):550-567. PubMed ID: 29293892
    [TBL] [Abstract][Full Text] [Related]  

  • 69. N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases.
    Snellman A; Lantero-Rodriguez J; Emeršič A; Vrillon A; Karikari TK; Ashton NJ; Gregorič Kramberger M; Čučnik S; Paquet C; Rot U; Zetterberg H; Blennow K
    Brain; 2022 Aug; 145(8):2834-2848. PubMed ID: 35311972
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
    Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
    Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Kaiserova M; Chudackova M; Prikrylova Vranova H; Mensikova K; Kastelikova A; Stejskal D; Kanovsky P
    Neurodegener Dis; 2021; 21(1-2):30-35. PubMed ID: 34695830
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
    Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
    Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
    Mattsson-Carlgren N; Grinberg LT; Boxer A; Ossenkoppele R; Jonsson M; Seeley W; Ehrenberg A; Spina S; Janelidze S; Rojas-Martinex J; Rosen H; La Joie R; Lesman-Segev O; Iaccarino L; Kollmorgen G; Ljubenkov P; Eichenlaub U; Gorno-Tempini ML; Miller B; Hansson O; Rabinovici GD
    Neurology; 2022 Mar; 98(11):e1137-e1150. PubMed ID: 35173015
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells.
    Woerman AL; Aoyagi A; Patel S; Kazmi SA; Lobach I; Grinberg LT; McKee AC; Seeley WW; Olson SH; Prusiner SB
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):E8187-E8196. PubMed ID: 27911827
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy.
    Piras A; Collin L; Grüninger F; Graff C; Rönnbäck A
    Acta Neuropathol Commun; 2016 Mar; 4():22. PubMed ID: 26936765
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy.
    Borroni B; Malinverno M; Gardoni F; Grassi M; Parnetti L; Agosti C; Alberici A; Premi E; Bonuccelli U; Gasparotti R; Calabresi P; Di Luca M; Padovani A
    J Alzheimers Dis; 2010; 22(1):195-203. PubMed ID: 20847421
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Machine learning-based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration.
    Koga S; Zhou X; Dickson DW
    Neuropathol Appl Neurobiol; 2021 Dec; 47(7):931-941. PubMed ID: 33763863
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.
    Kawamura K; Miyajima M; Nakajima M; Kanai M; Motoi Y; Nojiri S; Akiba C; Ogino I; Xu H; Kamohara C; Yamada S; Karagiozov K; Ikeuchi T; Kondo A; Arai H
    J Alzheimers Dis; 2021; 83(1):179-190. PubMed ID: 34275898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.